Neurophet Inc

Neurophet Inc has a liquidity position that is currently medium risk, with a current ratio of 3.61, indicating the company has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -21.6 billion KRW, and operating cash flow is also negative at -15.1 billion KRW, suggesting ongoing cash burn. The company's cash and equivalents stand at 4.1 billion KRW, but this is offset by long-term debt of 5.5 billion KRW, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics for Neurophet Inc are significantly negative, with a return on equity of -115.1% and a return on assets of -83.28%. These figures are well below the industry median for the Advanced Medical Equipment & Technology sector, which typically sees positive returns on equity and assets. The company's operating income is -16.5 billion KRW, and net income is -22.4 billion KRW, indicating substantial losses. Geographically and segment-wise, Neurophet Inc's revenue concentration is not disclosed in the available data. The company operates in the healthcare equipment segment, but no further breakdown of revenue by geographic region or product line is provided. This lack of transparency may limit the ability to assess the company's exposure to regional market risks or the performance of specific product lines. The company's growth trajectory is currently negative, with no disclosed revenue growth in the most recent fiscal year. The outlook for the next fiscal year is also uncertain, as the company continues to report losses and negative cash flows. The absence of positive revenue growth or improvement in profitability suggests a challenging path forward unless significant operational or strategic changes are implemented. Risk factors for Neurophet Inc include its high liquidity risk due to negative free and operating cash flows, as well as its negative net cash position after accounting for long-term debt. The company's dilution risk is currently low, but the potential for future dilution exists if the company needs to raise additional capital to fund operations or expand its business. No recent dilutive events have been disclosed, but the company's capital structure and financial position may necessitate future equity issuance. Recent events for Neurophet Inc include the continued financial losses and negative cash flows reported in the latest financial statements. No significant new product launches, regulatory approvals, or strategic partnerships have been disclosed in the available data. The company's recent filings and transcripts do not indicate any major developments that would suggest a turnaround in its financial performance.